



Novelion Therapeutics Inc.
Investor Relations Department
887 Great Northern Way, Suite 250
Vancouver V5T 4T5
Canada

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: NVLN

Last Trade:	3.43
Trade Time:	4:00 PM ET Mar 23, 2018
Change:	0.05 (+1.479%)
Day Range	3.26 - 3.46
52-Week Range	3.08 - 11.00
Volume	44,079

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Mar 15, 2018*
[Novelion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results](#)
- Mar 15, 2018*
[Novelion Therapeutics Subsidiary Enters into \\$20 Million Term Loan Agreement with Sarissa Capital and Broadfin Capital](#)
- Feb 28, 2018*
[Novelion Therapeutics Observes Rare Disease Day](#)
- Jan 30, 2018*
[Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals](#)
- Jan 24, 2018*
[Novelion Therapeutics Announces Cost Reduction Plans and Capital Structure Review](#)

Financials [\[View all \]](#)

- Mar 16, 2018*
[Annual Report \(10-K\)](#)
- May 1, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)